Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer

On June 15, 2020 Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, reported that it has appointed Dr. Hasan Jafri as Chief Medical Officer (CMO) (Press release, Aridis Pharmaceuticals, JUN 15, 2020, View Source [SID1234561117]). Dr. Jafri replaces Dr. Paul Mendelman who has been serving as the Company’s interim CMO since October, 2019 and will transition to the role of senior medical advisor to the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"It is a pleasure to welcome Dr. Jafri to the Aridis team as he brings extensive clinical, research and industry experience across the full spectrum of the infectious disease treatment landscape, especially in anti-infective immunotherapies," commented Vu Truong, Ph.D., Chief Executive Officer of Aridis Pharmaceuticals. "I also wish to extend gratitude to Dr. Mendelman for his tremendous contribution in helping maintain the development pace of our clinical programs and implementation of the Company’s APEX technology platform used in the discovery of COVID-19 mAbs and other antibodies against lung disease pathogens."

Dr. Jafri comes to Aridis from AstraZeneca, where he most recently served as Senior Medical Director, Clinical Research and Development, Microbial Sciences, Clinical Head of Antibacterial mAb Program, and Coordinator of the European Public-Private COMBACTE-NET & COMBACTE-MAGNET consortia focused on antibacterial drug development supported by the Innovative Medicines Initiative (IMI). During his tenure at AstraZeneca, he led the clinical development of the anti-bacterial monoclonal antibodies within the Serious Bacterial Infections Franchise, including its Phase 2 programs MEDI4893 (anti-S. aureus alphatoxin mAb) and MEDI3902 (anti-P. aeruginosa Psl/PcrV mAb). He also served as the AstraZeneca representative on the Infection Control Strategic Governance Group (SGG), an industry committee tasked with advising the European Commission and IMI on R&D priorities. In addition to the antibacterial programs, Dr. Jafri has been a leader in respiratory syncytial virus (RSV) R&D. Dr. Jafri has over 25 years of experience in clinical practice and research, especially in the area of serious healthcare associated and community acquired infections, respiratory viral infections and invasive fungal infections (in immunocompromised and immunocompetent hosts), and biomarker and translational research. He has been involved in the design and conduct of multiple Phase 1–4 clinical studies to assess novel small and large molecules against bacterial, viral and fungal pathogens. Prior to joining AstraZeneca, Dr. Jafri served as a Professor in the Department of Pediatric Infectious Diseases and the Department of Clinical Science Research at the University of Texas Southwestern Medical Center at Dallas. He was the Chief of Division of Clinical Pharmacology, Director of the Pediatric Infectious Diseases fellowship program, and Director of the NICHD Pediatric Pharmacology Research Center. Dr. Jafri has authored over 70 peer reviewed journal articles and presented over 100 original research abstracts at National and International Conferences.

"I’m excited to join Aridis especially at such a critical time within the infectious disease arena given the COVID-19 pandemic, the global antibiotic resistance challenges and the need for new innovative antibacterial therapies. I look forward to playing an integral role in advancing our pipeline of differentiated anti-infective treatments for multiple indications and bringing these novel and potentially lifesaving medicines to patients," commented Dr. Hasan Jafri, Chief Medical Officer of Aridis Pharmaceuticals. "I’m particularly passionate about antiviral and antibacterial immunotherapy using monoclonal antibodies after having spent the past decade working on this area at AstraZeneca/MedImmune and have helped advance multiple programs through global Phase 3 clinical studies."

Epsilen Bio appoints Julia Berretta as Chief Executive Officer and Mathieu Simon as Chairman of the Board

On June 15, 2020 Epsilen Bio, a biotechnology company developing transformative therapies for patients affected by underserved medical conditions through stable epigenetic silencing of genes involved in pathological processes, reported the appointments of Julia Berretta, Ph.D, as Chief Executive Officer, and Mathieu Simon, M.D., as Chairman of the Board (Press release, Epsilen Bio, JUN 15, 2020, View Source [SID1234561086]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company also announced it has entered into a strategic collaboration with the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), a world-renowned research center devoted to gene therapy, directed by Professor Luigi Naldini. Within the collaboration Epsilen Bio will further develop the epigenetic silencing technology with the group of Epigenetic Regulation and Targeted Genome Editing led by Dr. Angelo Lombardo, and exclusively in-licensed by Epsilen Bio.

The announcements follow the successful close of a seed financing of €2.3 million from Sofinnova Partners, a leading European life sciences venture capital firm, through the Sofinnova Telethon Fund. The fund is the largest in Italy dedicated to early-stage biotech startups targeting cures for rare and genetic diseases.

Dr. Simon and Dr. Berretta join Board Members Paola Pozzi, Partner at Sofinnova Partners, Luca Guidotti, Deputy Scientific Director of the IRCCS Ospedale San Raffaele, and Francesca Pasinelli, CEO of Fondazione Telethon and Board Observer.

Dr. Berretta is also CEO of Genespire, a gene therapy company that is part of a series of investments recently made by Sofinnova Partners. Additionally, she is an independent Board member of Treefrog Therapeutics, an innovative stem cell company. Previously, Dr. Berretta was part of the Executive Committee of Cellectis S.A., a Nasdaq-listed clinical stage gene editing company developing CAR-T cell therapies for cancer, where she led business development as well as strategic planning.

Dr. Simon is Chairman of the Board of Idorsia and Independent Board Member of VAXIMM and Lysogene. He is also a member of the AFFIMED supervisory board. Previously, Dr. Simon was Chief Operating Officer of Cellectis SA and CEO of Cellectis Therapeutics. He was the former head of global pharma operations at Pierre Fabre and also held EU regional management roles and senior corporate functions at Wyeth Pharmaceuticals.

"We are excited to have Dr. Berretta and Dr. Simon joining Epsilen Bio," said Ms. Pozzi. "These appointments add both an industrial and an international perspective to the company, and we are delighted to support such a distinguished global team working on highly transformative science."

Epsilen Bio’s scientific co-founder, Dr. Angelo Lombardo, added, "Dr. Berretta and Dr. Simon have a deep knowledge of the pharmaceutical and the biotechnology industry. Their expertise will be crucial in helping to translate the science we developed at SR-Tiget into candidate therapeutic products for patients affected by underserved medical conditions".

"I am extremely pleased to join Epsilen Bio as Chairman of the Board," Dr. Simon said "The company’s unique technology of "episilencing," developed at SR-Tiget by Dr. Lombardo and Pr. Naldini, has the potential to be a game changer in the field given its versatility and applicability to a variety of diseases."

Vaxart, Inc. Appoints New CEO to Accelerate Advancement of COVID-19 and Other Programs

On June 15, 2020 Vaxart, Inc. ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, reported that effective it has appointed Andrei Floroiu as Chief Executive Officer (Press release, Vaxart, JUN 15, 2020, View Source [SID1234561102]). Mr. Floroiu is a highly experienced biopharma executive with a proven track record of value creation, with substantial financial, strategic and operational experience in the vaccine and biopharmaceutical industry. He has served as a member of Vaxart’s Board of Directors since April 2020 and will continue on the board while serving as Chief Executive Officer. Wouter Latour, MD will remain as Chairman of the Board and a director of the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am delighted to welcome Andrei to Vaxart and want to express my deepest confidence in him as we transition Vaxart’s leadership," said Dr. Latour. "It has been an honor to lead this incredibly talented team and advance the clinical programs of the Company for the last eight years, and the Board of Directors and I are looking forward to working with Andrei and the management team to drive the Company to the next stage of growth."

Mr. Floroiu was most recently with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine. Prior to Agenus, Mr. Floroiu was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. Mr. Floroiu also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, a leading management consultancy. Mr. Floroiu holds an MBA from the Wharton School, an MSc from the University of Maryland, and an Engineering degree from the Politechnica University of Bucharest.

"This is an exciting time for Vaxart, with tremendous prospects for growth and value creation in the new world ushered in by the coronavirus crisis," said Andrei Floroiu. "Wouter and the Vaxart team brought the company to the remarkable position of playing a potentially crucial role in the reopening of America, and the world, by rapidly advancing the development of what could be the most effective and most convenient COVID-19 vaccine. I am convinced that our work on COVID-19 will further validate the unique potential of Vaxart’s oral vaccine technology against other viral threats and as a rapid response pandemic platform. Our strong balance sheet, with almost $30 million in cash as of March 31st, enables us to intensify our efforts, while also building upon the interest in the Company’s disruptive vaccine platform."

"With Andrei’s appointment, we are pleased to have a seasoned executive with experience in vaccines and business development to build out the Company and set it on a path of sustainable growth," said Steven Boyd, a member of Vaxart’s Board of Directors. "As Vaxart’s largest institutional investor, and having personally known Andrei since we both worked at McKinsey, I have great confidence in his ability to generate substantial shareholder value by unlocking the Company’s tremendous potential. Vaxart has a strong balance sheet, a recurring royalty stream from Inavir marketed by Daiichi Sankyo to provide working capital, and multiple potential partnership opportunities."

Oncopeptides Reports Positive Results From Full Data Set of Phase 2 HORIZON Trial in Triple-class Refractory Multiple Myeloma Patients

On June 15, 2020 Oncopeptides AB (Nasdaq Stockholm: ONCO) reported that the full top-line results from the pivotal phase 2 HORIZON study, evaluating intravenous melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma (RRMM), have been presented at the ongoing 25th European Hematology Association (EHA) (Free EHA Whitepaper) meeting, EHA (Free EHA Whitepaper) (Press release, Oncopeptides, JUN 15, 2020, View Source [SID1234561118]). The results support the NDA submission to the US Food and Drug Administration, FDA, for accelerated approval of melflufen. The Company is on track to submit the application to FDA by the end of Q2, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oncopeptides will host a webcast on Tuesday, June 16 at 10.00 (CET) to provide comments on the full top-line results. The webcast can be followed via the link: View Source

All data were confirmed by the Independent Review Committee (IRC), with only minimal discordance.

Melflufen is a first-in-class anticancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. The results from the HORIZON study demonstrates that melflufen in combination with dexamethasone, have the potential to provide a therapeutic option for patients with relapsed refractory multiple myeloma (RRMM) that are hard to treat and have a poor prognosis, including patients with triple class refractory myeloma and patients with Extramedullary Disease. Responses were durable and often deepened with prolonged treatment, suggesting that patients could benefit from staying on treatment for as long as possible. The results are consistent with previously reported data, while no new safety concerns were identified. The full poster presentation is available on Oncopeptides’ website: View Source

"The HORIZON data is an important milestone for Oncopeptides and further validates our Peptide-Drug Conjugate platform", says Klaas Bakker, MD and CMO of Oncopeptides. "The results are in line with results from previous interim analyses. Notably, the PFS of 8.5 months in responding patients (both all treated and triple-class refractory), was materially higher than the DOR, which is explained by the relatively long-time it took for patients to respond (median 1.9 months). This is very encouraging for patients with an unmet need; ultimately this is the period patients benefit from treatment with melflufen. The fact that the treatment also seems to be well tolerable makes this a potentially attractive treatment option for a fast-growing patient population with a significant unmet medical need".

This information was submitted for publication at 08:00 (CET), June 15, 2020.

About the HORIZON (OP-106) study

In the pivotal phase 2 HORIZON study 157 multiple myeloma patients have been enrolled and evaluated. The study was fully recruited in October 2019 and the final data cut was made on January 14th. The patients in the study are refractory to pomalidomide and/or daratumumab after failing on immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). The HORIZON study population includes subgroups of patients who were triple-class refractory and/or had EMD and/or had cytogenetic high-risk features.

About melflufen

Melflufen (INN melphalan flufenamide) is a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately cleaved by peptidases to deliver an entrapped hydrophilic alkylator payload. Peptidases play a key role in protein homeostasis and feature in cellular processes such as cell-cycle progression and programmed cell death. In vitro, melflufen is 50-fold more potent in myeloma cells than the alkylator payload itself due to the increased intracellular alkylator concentration. Melflufen displays cytotoxic activity against myeloma cell lines resistant to other treatments, including alkylators, and has also demonstrated inhibition of DNA repair induction and angiogenesis in preclinical studies.

AbGenomics Holding Inc. Announces Company Name Change to AltruBio Inc

On June 15, 2020 AbGenomics Holding Inc., a clinical stage biotech company, announced today that the company will be operating under a new name, AltruBio Inc., effective immediately (Press release, AltruBio, JUN 15, 2020, View Source [SID1234572765]). Its headquarters will remain in Redwood City in the San Francisco Bay Area, and its Taiwanese subsidiary will also reflect the rebranding operating under AltruBio Taiwan, Inc.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new name reflects a refocusing of the company with recent changes to its management team, board of directors, and overall strategy. Over the past year, under the leadership of Chairman Dr. Patrick Y. Yang, who is an industry veteran, the company recruited a new slate of directors with depth and breadth of experience in the biopharmaceuticals industry. In December, the company announced the hiring of Dr. Judy Chou as President and Chief Executive Officer. Since starting in January, Dr. Chou has revamped the company, focusing on its autoimmune disease pipeline and the potential to quickly realize value for patients and stakeholders in the Steroid-refractory acute Graft versus Host Disease (SR-aGVHD) space.

President and CEO, Dr. Judy Chou, stated "I am pleased to announce the rebranding of the company to AltruBio Inc. This reflects the new beginning the company has made and the values it seeks to uphold. The name speaks for our belief that our drugs should truly benefit the patients in an altruistic way with the desirable efficacy without compromising safety. It also represents our operations for being ‘all true’ to our patients, investors, partners, and employees"